Table 2

 Comparison of features from longitudinal clinic data and drug trials of psoriatic arthritis (PsA)

PsA Clinic17*Trials
Sulfasalazine29Leflunomide30Etanercept 231Etanercept 332Infliximab 233Infliximab 334
*Updated information from the University of Toronto PsA Clinic.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; NA, not available.
Demographic features
    No of patients65022119060205102200
    Male/female364/286169/51112/7834/26105/10060/104NA
    Duration of psoriasis14.619.51819NANA
    Duration of arthritis7.51210.5109165.4
    Age at first visit (years)43.5504845474647
Clinical features
    No of patients65022119060205102200
    No of tender joints10131920NA2023
    No of swollen joints3NA1214NA1312
    Spondylitis37%74%NANA3%NA8%
    Dactylitis34%NANANANANA40%
Acute phase reactants and health status
    No of patients34922119060205102200
    Mean ESR/CRPNANA18/1.3NA30/6NA
    HAQ0.68NA1.1NA1.11.11.1